Opportunity Information: Apply for RFA CA 21 011
This funding opportunity (RFA-CA-21-011) from the National Institutes of Health, through the National Cancer Institute (NCI), supports revision applications to existing, active NCI P01 Program Project Grants. In other words, it is not meant for brand-new P01s or unrelated projects; it is designed for teams that already hold an NCI-funded P01 and want to add a well-justified expansion that strengthens or speeds up the parent program project. The specific goal is to accelerate the science being done in the current P01 by bringing in a novel technology or technical approach that was developed with NCI Innovative Molecular Analysis Technologies (IMAT) program support. The emphasis is on using IMAT-backed tools to push the parent research forward, either by extending the original research questions in a meaningful way or by materially increasing the pace, rigor, or reach of the ongoing work.
A central theme of this FOA is independent validation and practical readiness. The NCI is using these awards as an incentive for outside groups (the P01 teams) to test and validate emerging IMAT-supported technologies in real research settings and help demonstrate that the technologies are suitable for broader use by the relevant cancer research communities. The intent is not simply to adopt a shiny new instrument, but to generate credible evidence that the technology works as expected, adds value, and can be deployed effectively within cancer research workflows. Because it sits within the IMAT program ecosystem, the FOA also reinforces interdisciplinary collaboration, encouraging partnerships that blend technology development strengths with cancer biology, translational research, and other applied cancer research expertise.
The FOA uses the NIH grant mechanism and is categorized under health and education (CFDA 93.394). The title notes "P01 Clinical Trial Optional," meaning the proposed revision work may include a clinical trial component if it fits the goals and policies of the parent P01 and the FOA, but a clinical trial is not inherently required. The key requirement is that the application is a revision to an active NCI P01 and that the revision is specifically justified by the incorporation of an IMAT-supported technology to expand or accelerate the parent study.
Eligibility is broad in the sense that many organization types can apply (as long as they meet the core requirement of being a currently funded NCI P01 awardee submitting a revision). Eligible applicant organization categories listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other types of eligible entities. The announcement also highlights a range of mission- or population-focused institutions and groups as eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
At the same time, the FOA draws clear boundaries around foreign involvement. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply as applicant organizations, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined by the NIH Grants Policy Statement, which means a U.S. applicant may include certain foreign activities or collaborations when appropriately justified and compliant with NIH policy, even though a foreign institution cannot be the primary applicant.
Administratively, the opportunity was created on 2020-11-24 and had an original closing date of 2021-09-29. The listing does not provide an award ceiling or expected number of awards in the provided source data, so those specifics are not stated here. The overall message of the FOA is straightforward: NCI wants existing P01 teams to meaningfully boost the impact and momentum of their ongoing cancer research by integrating and validating promising IMAT-supported technologies, helping move those tools from development into reliable, community-ready use.Apply for RFA CA 21 011
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on 2020-11-24.
- Applicants must submit their applications by 2021-09-29. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity (RFA-CA-21-011) about?
This opportunity from the National Institutes of Health (NIH), through the National Cancer Institute (NCI), supports revision applications to existing, active NCI P01 Program Project Grants. The purpose is to expand and/or accelerate the science already underway in the parent P01 by incorporating a technology or technical approach that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program.
Is this for new (brand-new) P01 applications?
No. The FOA is specifically designed for teams that already hold an active NCI-funded P01 and want to submit a revision. It is not intended for brand-new P01 applications or for unrelated projects outside the scope of the current P01.
What kind of work is NCI trying to support through this revision?
The revision should be a well-justified expansion that strengthens the parent program project by bringing in an IMAT-supported technology or technical approach. The expectation is that the addition will either:
- Meaningfully extend the original research questions of the P01, and/or
- Materially increase the pace, rigor, or reach of the ongoing cancer research.
What is the key technology requirement in this FOA?
The revision must be specifically justified by incorporating a novel technology or technical approach that was developed with support from the NCI IMAT program. The FOA emphasizes using IMAT-backed tools to push the parent P01 research forward.
What does the FOA mean by "independent validation"?
A central theme is that NCI is using these awards to incentivize outside groups (the P01 teams) to test and validate emerging IMAT-supported technologies in real research settings. The intent is to generate credible evidence that the technology:
- Works as expected,
- Adds clear value to cancer research workflows, and
- Is suitable for broader use by relevant cancer research communities.
Is the goal simply to adopt a new tool or instrument?
No. The FOA is not focused on adopting a "shiny new instrument" for its own sake. It is focused on producing credible, practical evidence that an IMAT-supported technology can be deployed effectively and reliably within cancer research workflows, helping demonstrate community readiness.
How does this FOA relate to the IMAT program?
The FOA is part of the IMAT program ecosystem in the sense that it promotes taking IMAT-supported technologies from development into practical use. It also reinforces interdisciplinary collaboration, encouraging partnerships that blend technology development strengths with cancer biology, translational research, and other applied cancer research expertise.
Does the revision need to "expand" the parent P01, or can it focus on "accelerating" it?
The FOA describes both as acceptable goals. The revision should strengthen or speed up the parent program project by integrating an IMAT-supported technology, either by extending the research questions in a meaningful way or by increasing the pace, rigor, or reach of the ongoing work.
Are clinical trials required under this opportunity?
No. The FOA title notes "P01 Clinical Trial Optional", meaning the proposed revision work may include a clinical trial component if it fits the goals and policies of the parent P01 and the FOA, but a clinical trial is not inherently required.
What grant mechanism and category does this opportunity use?
The FOA uses the NIH grant mechanism and is categorized under health and education with CFDA 93.394.
Who is eligible to apply?
Eligibility is broad across many organization types, but the core requirement is specific: the applicant must be a currently funded NCI P01 awardee submitting a revision to an active NCI P01.
What types of organizations are listed as eligible applicants (assuming they meet the active NCI P01 revision requirement)?
The FOA lists a wide range of eligible applicant organization categories, including:
- State, county, city, or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments and other tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofits with or without 501(c)(3) status (other than institutions of higher education)
- For-profit organizations (other than small businesses)
- Small businesses
- Other types of eligible entities
Are specific mission- or population-focused institutions mentioned as eligible?
Yes. The FOA highlights eligibility for a range of mission- or population-focused institutions and groups, including:
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Faith-based or community-based organizations
- Eligible federal agencies
- Regional organizations
- U.S. territories or possessions
Can a foreign (non-U.S.) organization apply as the main applicant?
No. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply as applicant organizations for this FOA.
Can a non-domestic component of a U.S. organization apply?
No. Non-domestic components of U.S. organizations are also not eligible to apply as applicant organizations under this FOA.
Are foreign components allowed at all in projects funded under this FOA?
Yes, foreign components are allowed as defined by the NIH Grants Policy Statement. In practical terms, a U.S. applicant may include certain foreign activities or collaborations when appropriately justified and compliant with NIH policy, even though a foreign institution cannot be the primary applicant.
What is the main purpose of supporting revisions rather than separate new awards?
The FOA is designed to strengthen and speed up the science already underway in an active NCI P01. The focus is on accelerating the parent P01 by integrating and validating an IMAT-supported technology in a real research setting, helping move that technology toward reliable, community-ready use.
When was this opportunity created and when did it close?
The opportunity was created on 2020-11-24 and had an original closing date of 2021-09-29.
Does the provided information include the award ceiling or expected number of awards?
No. The provided source data does not state an award ceiling or the expected number of awards for this FOA.
What is the simplest way to summarize the FOA's intent?
NCI wants existing NCI P01 teams to meaningfully boost the impact and momentum of their ongoing cancer research by integrating and independently validating promising IMAT-supported technologies, generating practical evidence that those tools are ready for broader use by the cancer research community.
Browse more opportunities from the same category: Education, Health
Next opportunity: Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)
Previous opportunity: NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 21 011
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 21 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) Apply for RFA CA 21 010 Funding Number: RFA CA 21 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed) Apply for RFA CA 21 001 Funding Number: RFA CA 21 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) Apply for RFA CA 21 014 Funding Number: RFA CA 21 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Cellular Cancer Biology Imaging Research (CCBIR) Program (U54, Clinical Trial Not Allowed) Apply for RFA CA 21 002 Funding Number: RFA CA 21 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,250,000 |
| Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) Apply for RFA DA 21 031 Funding Number: RFA DA 21 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) Apply for RFA DA 21 032 Funding Number: RFA DA 21 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Music and Health: Understanding And Developing Music Medicine (R21 Clinical Trial Optional) Apply for PAR 21 099 Funding Number: PAR 21 099 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 - Clinical Trials Optional) Apply for RFA DA 21 015 Funding Number: RFA DA 21 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: $256,580 |
| Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional) Apply for RFA DA 21 016 Funding Number: RFA DA 21 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $256,580 |
| Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional) Apply for PAR 21 100 Funding Number: PAR 21 100 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 - Clinical Trials Not Allowed) Apply for RFA DA 21 041 Funding Number: RFA DA 21 041 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 - Clinical Trials Not Allowed) Apply for RFA DA 21 040 Funding Number: RFA DA 21 040 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed Apply for PAR 21 104 Funding Number: PAR 21 104 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required) Apply for PAR 21 105 Funding Number: PAR 21 105 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional) Apply for RFA MH 21 145 Funding Number: RFA MH 21 145 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required) Apply for RFA DA 21 030 Funding Number: RFA DA 21 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,750,000 |
| Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) Apply for PA 21 110 Funding Number: PA 21 110 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) Apply for RFA DA 22 004 Funding Number: RFA DA 22 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed) Apply for RFA DA 22 006 Funding Number: RFA DA 22 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) Apply for RFA CA 21 030 Funding Number: RFA CA 21 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 21 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.